Abstract
The aim of this study was to investigate the effect of citalopram, a selective serotonin reuptake inhibitor, on the sensitivity of rat vas deferens alpha2-adrenoceptors and to compare it with the effects of serotonin and the dual noradrenaline-serotonin uptake inhibitor duloxetine. To this end, we studied the inhibitory effect of the alpha2-adrenoceptor agonist bromoxidine on the electrically induced contraction of the vas deferens. Citalopram (1, 3 x 10(3) and 3 x 10(4) nM) applied in-vitro significantly attenuated the concentration-response inhibition induced by activation of alpha2-adrenoceptors on the electrically evoked contraction of the vas deferens (concentration of the agonist required to promote 50% of the maximal effect, EC50, for bromoxidine increased by 232%, 421% and 818%, respectively). Similarly, serotonin also attenuated the concentration-response inhibition mediated by presynaptic alpha2-adrenoceptors (96% increase in EC50). Acute and long-term systemic administration of citalopram and duloxetine also produced a loss in the sensitivity of alpha2-adrenoceptors to bromoxidine (EC50 for bromoxidine increased by 97% and 144%, respectively, after citalopram, and by 214% and 167% after duloxetine). In addition, we o...Continue Reading
References
Aug 25, 1992·European Journal of Pharmacology·K Smith, J R Docherty
Dec 1, 1990·The Biochemical Journal·R J MoureyS H Snyder
Jul 1, 1989·Physiological Reviews·K StarkeH Kilbinger
Oct 1, 1988·Neurochemical Research·S M Celuch, B D Sloley
Dec 1, 1986·British Journal of Pharmacology·J A García-Sevilla, J K Zubieta
Jan 1, 1968·Zeitschrift für Zellforschung und mikroskopische Anatomie·G J Etcheverry, L M Zieher
Nov 1, 1969·Agents and Actions·Y Hotta
Dec 22, 1983·Proceedings of the Royal Society of London. Series B, Containing Papers of a Biological Character·J W Black, P Leff
Jan 1, 1984·Psychopharmacology·J HyttelJ Arnt
Jan 1, 1981·Psychopharmacology·W KostowskiM Hauptmann
Apr 4, 1996·European Journal of Pharmacology·B Petersen, A Mørk
Aug 1, 1996·Psychopharmacology·E P PälvimäkiJ Hietala
Jul 1, 1997·Naunyn-Schmiedeberg's Archives of Pharmacology·M GobbiT Mennini
Feb 12, 1998·British Journal of Pharmacology·J PinedaJ A García-Sevilla
Aug 28, 1998·British Journal of Pharmacology·Z A Hughes, S C Stanford
Mar 30, 1999·Life Sciences·L BuschE Borda
Oct 3, 1999·Journal of Clinical Psychopharmacology·P Popik
Dec 22, 1999·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·L BuschE Borda
Aug 29, 2000·Journal of Autonomic Pharmacology·N I KalyoncuS Karaoglu
Jun 1, 1976·Neuroscience·L FuenmayorE Romero
Jul 17, 2001·Biological Psychology·F Holsboer
Jul 31, 2001·International Journal of Impotence Research·K E Andersson
Mar 15, 2002·Drugs·Antona J WagstaffKaren L Goa
Jul 12, 2002·British Journal of Pharmacology·Linda ClearyJames R Docherty
Jan 9, 2003·Expert Opinion on Investigational Drugs·P FarvoldenR W Lam
Aug 7, 2003·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Ersin YarisRasin Ozyavuz
Nov 25, 2003·The Annals of Pharmacotherapy·David E Adson, Michael Kotlyar
Mar 11, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Gerard SanacoraDennis S Charney
May 19, 2004·Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists·Paolo Cassano, Maurizio Fava
Jun 25, 2005·European Journal of Pharmacology·Laura GrandosoLuisa Ugedo